去纤维钠国内价格

(Defibrinoside) is a mixture of single-stranded deoxyoligonucleotide sodium salts produced by controlled depolymerization of porcine intestinal mucosal genomic DNA. Its mechanism of action is complex and has not yet been fully elucidated.

Defibrotide is the first drug approved by the U.S. FDA for the treatment of severe hepatic veno-occlusive disease. It is used for adult or pediatric patients with hepatic venous obstruction (VOD) who have undergone blood or bone marrow hematopoietic stem cell transplantation (HSCT) and are accompanied by renal or lung function abnormalities. The drug has also received "orphan drug" designation.

Defibrinated sodium is not on the market in my country, so there is currently no domestic price to speak of. The overseas version of defibrinated sodium is equivalent to RMB 22,000. The price will change due to factors such as exchange rates. If it is inconvenient for patients to go abroad, they can consult our Medical Companion Travel Overseas Medical Consulting Service Company for purchasing methods.

Defibrotide sodium is an injectable drug. Many patients do not understand its use after purchasing this drug. It should be noted that before administration, it is confirmed that the patient has not experienced clinically significant bleeding and is hemodynamically stable on no more than one vasopressor. Administer defibrinated sodium by constant intravenous infusion over a 2-hour period. It is prohibited to use if you are allergic to defibrinated sodium (defibrotide) or its components. Hypersensitivity reactions have occurred in less than 2% of patients treated with defibrotide sodium. These reactions include rash, urticaria, and angioedema. If a severe hypersensitivity reaction occurs, discontinue medication, treat according to standard medical care, and monitor until symptoms resolve.

It is the first drug in the United States to treat severe hepatic veno-occlusive disease and is currently recognized as the most promising new drug for the treatment of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). Multiple clinical trials have confirmed the effectiveness of defibrinated sodium in the treatment of HVOD.

Recommended related hot articles: /newsDetail/71760.html